Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3847673 | 0.84 | HPGD (0.57) | HPGDRECQLHDAC3HDAC4HDAC1 | |
| SCHEMBL3875386 | 0.84 | ALDH1A1 (0.59) | HPGDRECQLHDAC3HDAC4HDAC1 | |
| SCHEMBL5354411 | 0.81 | KMT2A (0.56) | HPGDRECQLHDAC3HDAC4HDAC1 | |
| SCHEMBL9078412 | 0.81 | HPGD (0.54) | HPGDRECQLHDAC3HDAC4HDAC1 | |
| SCHEMBL11676181 | 0.81 | HPGD (0.64) | HPGDRECQLHDAC3HDAC4HDAC1 | |
| SCHEMBL13988049 | 0.81 | HPGD (0.54) | HPGDRECQLHDAC3HDAC4HDAC1 | |
| SCHEMBL9447401 | 0.81 | HPGD (0.54) | HPGDRECQLHDAC3HDAC4HDAC1 | |
| SCHEMBL8599690 | 0.80 | HPGD (0.70) | HPGDRECQLHDAC3HDAC4HDAC1 | |
| SCHEMBL754989 | 0.80 | ALDH1A1 (0.69) | HPGDRECQLHDAC3HDAC4HDAC1 | |
| SCHEMBL8075060 | 0.80 | HPGD (0.53) | HPGDRECQLHDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102234231-B | 1-substituted-2-substituted-4- aryl substituted-butyl-2-alkene 1, 4-diketone compound, its preparation method and application | SHANGHAI INST MATERIA MEDICA | 2015-01-07 | — | — | CN | disclosed |
| US-8778948-B2 | Substituted phenylpiperazinyl aralkylalcohol derivatives, pharmaceutical compositions containing such derivatives and uses thereof | NHWA Pharma, Corporation (CN) | 2014-07-15 | — | — | US | disclosed |
| US-8492548-B2 | Alkaloid aminoester derivatives and medicinal compositions thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-07-23 | — | — | US | disclosed |
| EP-1861359-B1 | N-(N-SULFONYLAMINOMETHYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN | PFIZER (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20110311458-A1 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-12-22 | — | — | US | disclosed |
| US-20110294822-A1 | Substituted Phenylpiperazinyl Aralkylalcohol Derivatives, Pharmaceutical Compositions Containing Such Derivatives and Uses Thereof | NHWA PHARMA. CORPORATION (CN) | 2011-12-01 | — | — | US | disclosed |
| US-7915448-B2 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7622589-B2 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7569579-B2 | for inhibition of HIV replication and treatment of acquired immune deficiency syndrome | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| US-7452992-B2 | inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS); 1-((1R,5S)-8-{2-[3-(2,2-dimethylpropanoyl)-6-phenyl-1,3-oxazinan-6-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-18 | — | — | US | disclosed |
| US-7271172-B2 | Pyrrolidine and azetidine compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-20060211741-A1 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER, INC. | 2006-09-21 | — | — | US | disclosed |
| US-5155268-A | Antiarrhythmic N-aminoalkylene alkyl and aryl sulfonamides | THE UPJOHN COMPANY (US) | 1992-10-13 | — | — | US | disclosed |
| EP-0164865-B1 | N-(AMINOALKYLPHENYL)SULFONAMIDES THEIR PREPARATION AND THERAPEUTIC USE | THE UPJOHN COMPANY (US) | 1988-12-21 | — | — | EP | disclosed |
| EP-0164865-A1 | N-(Aminoalkylphenyl)sulfonamides their preparation and therapeutic use | THE UPJOHN COMPANY (US) | 1985-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211741-A1 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | CNR1, HVCN1, CNR2 | HPGD 3078/4885RECQL 4357/4885HDAC3 1004/4885 |
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | CNR1, HVCN1, CNR2 | HPGD 3027/4885RECQL 4393/4885HDAC3 1003/4885 |
| US-20110311458-A1 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | CHRM3, CHRM5, CHRM2 | HPGD 1600/4885RECQL 3236/4885HDAC3 2887/4885 |
| US-20110294822-A1 | Substituted Phenylpiperazinyl Aralkylalcohol Derivatives, Pharmaceutical Compositions Containing Such Derivatives and Uses Thereof | OPRL1, OPRK1, OPRD1 | HPGD 1558/4885RECQL 2155/4885HDAC3 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.